Suchergebnisse
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Shares of Silence Therapeutics SLN have surged 107% over the past six months, driven by investor optimism around the company's advancing RNA interference (siRNA) pipeline, upcoming clinical data


